ArticleTherapeutic advances in neurological disorders2025

Access, satisfaction, adherence and safety to subcutaneous natalizumab compared to intravenous natalizumab in multiple sclerosis in a real-life cohort: first report from Latin America.

Berenice A Silva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.